Skip to content

Study · Not a test of the peptide alone · 2015

1 result

[Optimization of pharmacological therapy for weakness syndrome in incurable patients].

Ryazankina AA, Rozengard SA, Glushchenko VA, Karitsky AP, Kvashnin AV

Voprosy onkologii1 Jan 2015

PMID26087610 (opens in a new tab)PepBankPUB-26087610
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Bromantane.

  1. 01HumanNot a test of Bromantane aloneNon-randomized trialEfficacy outcome

    In incurable cancer patients, ladasten with ondansetron and agomelatine treated fatigue/weakness syndrome more effectively than standard therapy.

    In plain wordsIn incurable cancer patients, the ladasten, ondansetron and agomelatine regimen improved fatigue treatment versus standard therapy.

    Peptide
    Bromantane
    Outcome
    Direction not reportedFatigue/weakness syndrome
    Study

    n: not reported in source

    Comparator
    standard therapy
    Outcome group
    Exercise and physical function · Whole body

    Source sentences

    Summary
    It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.